Interní Med. 2001; 3(9): 11-15

Možnosti hormonální substituční léčby

MUDr. Jaroslav Jeníček1,2
1 Lékařský dům Praha, Centrum klimakterické medicíny
2 Gynekologicko-porodnická klinika III. LF UK a FNKV, Praha

Keywords: Hormonal substitional treatment, compliance, benefit, risk, side effects.

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jeníček J. Možnosti hormonální substituční léčby. Interní Med. 2001;3(9):11-15.

Autor podává v přehledném článku svůj názor na indikace a prospěch léčby. Jsou velmi podrobně zmíněna možná schémata hormonální léčby a snaha o individualizaci hormonální substituční léčby. V části věnované rizikům a nežádoucím reakcím hormonální léčby jsou literární údaje konfrontovány s praktickými zkušenostmi autora.

Hormonal Substitutional Treatment Possibilities

The author presented in his article a revi ew and his objective to indication and benefit of such treatment. Very detailed are described the outlines of hormonal treatment possibilities aimed to individualize the hormonal substituted therapy. In the part where the risk and side effects of this treatment are discu sed the author provides a comparement between the literature and his own practical opinion.

Lékařský dům Praha, Centrum klimakterické medicíny

Gynekologicko-porodnická klinika III. LF UK a FNKV, Praha

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Trunkát, I.: Hormonální substituční terapie. Causa Subita, 11, 1999, s. 5-7.
    2. Zahrádková, J.: Problematika žen v menopauze. Causa Subita, 6, 1999, s. 17-19.
    3. Donát, J.: Hormonální substituční terapie, DoMeNa, Hradec Králové 1999, s. 35-55.
    4. Grady D et al.: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117: s. 1016-37. Go to original source... Go to PubMed...
    5. Grodstein F., Stampfer MJ., Golditz GA. et al:Postmenopausal Hormone Therapy and mortality, N Engl J Med 336: s. 1769-1775, 1997. Go to original source... Go to PubMed...
    6. Hulley S., Grady D., Bush T. et al: Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women, JAMA August 19, 1998 Vol 280, No 7. Go to original source... Go to PubMed...
    7. Paganni-Hill A, Henderson VW: Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 156: s. 2213-2217, 1996. Go to original source...
    8. Grodstein F, Colditz GA, Stampfer MJ.: Postmenopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc. 1996, 335: s. 453-461. Go to original source... Go to PubMed...
    9. The Eye-Disease Case-Control Study Group. Risk factors for neovascular agerelated macular degeneration. Arch Ophtalmol. 1992, 110: s. 1701-1708. Go to original source... Go to PubMed...
    10. Vingerling JR, Dielemans I, Witteman CM, et al.: Macular degeneration and early menopause: case-control study. Br Med J. 1995, 310:s. 1570-1571. Go to original source... Go to PubMed...
    11. Calle EE., Miracle-McMahill HL., Thun MJ., Heath CW. Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995, 87: s. 517-523. Go to original source... Go to PubMed...
    12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997, 350: s. 1047-1059. Go to original source...
    13. Eden JA, Bush T, Nand S, Wren BG. A case-controlled study of combined continuous oestrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause. 1995, 2: s. 67-72. Go to original source...
    14. Grady D, Gebredsadik T, Kerlikowske K et al. Hormonereplacement therapy and endometrial cancer risk: a metaanalisis. Obstet Gynecol. 1995, 85: s. 304-313. Go to original source... Go to PubMed...
    15. Donát, J.: Aktuální pohled na rizika hormonální substituční terapie. Lege Artis, 2. 1. 2001, s. 35-38.
    16. Donát, J. : Hormonální substituční terapie, DoMeNa, Hradec Králové 1999, s. 75.
    17. Lufkin EG et al. Relativní výhody transdermální a orální estrogenové erapie v různých klinických situacích. Mayo Clinic Proc 1994, 69: 131-135. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.